• Je něco špatně v tomto záznamu ?

Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience

J. Cincibuch, C. Neoral, R. Aujeský, V. Srámek, P. Schneiderka, H. Studentová, B. Melichar, M. Kohoutek, J. Stráznická, R. Vrba, J. Juránová, P. Flodr, J. Machácek, K. Cwiertha

. 2010 ; 57 (102-103) : 1145-1149.

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12027005

BACKGROUND/AIMS: The trimodality therapy including chemotherapy, external beam radiation and surgery is widely accepted as the standard of care in patients with locoregional esophageal carcinoma. METHODOLOGY: We have performed a retrospective analysis of patients with locoregional esophageal carcinoma treated with chemoradiation. RESULTS: One-hundred and fifty-two consecutive patients with non-metastatic adenocarcinoma or squamous cell esophageal carcinoma treated with chemoradiation were included in the present analysis. The median survival of the whole group was 12 months. The estimated 3- and 5-year survival rates were 24% and 19%, respectively. On multivariate analysis, female sex, weight loss and serum albumin were independent negative predictors of survival. Among 140 patients who survived more than 3 months, weight loss, female sex and therapy with paclitaxel were negatively associated with prognosis, and among 109 patients surviving more than 6 months the dose of cisplatin and surgery were independent prognostic factors. Pathologic complete response was not predictive of prognosis. CONCLUSIONS: Long-term survival is obtained in only about 20% of patients with carcinoma of the esophagus treated with chemoradiation. Female sex, weight loss and low serum albumin are independent indicators of poor prognosis. Among treatment-related factors, higher dose of cisplatin and esophagectomy were independent predictors of better prognosis, while administration of paclitaxel was associated with poor prognosis.

000      
00000naa a2200000 a 4500
001      
bmc12027005
003      
CZ-PrNML
005      
20170427080924.0
007      
ta
008      
120816s2010 gr f 000 0#eng||
009      
AR
035    __
$a (PubMed)21410047
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Cincibuch, Jan $7 xx0135583 $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
245    10
$a Prognostic factors in patients with esophageal carcinoma treated with chemoradiation: single center experience / $c J. Cincibuch, C. Neoral, R. Aujeský, V. Srámek, P. Schneiderka, H. Studentová, B. Melichar, M. Kohoutek, J. Stráznická, R. Vrba, J. Juránová, P. Flodr, J. Machácek, K. Cwiertha
520    9_
$a BACKGROUND/AIMS: The trimodality therapy including chemotherapy, external beam radiation and surgery is widely accepted as the standard of care in patients with locoregional esophageal carcinoma. METHODOLOGY: We have performed a retrospective analysis of patients with locoregional esophageal carcinoma treated with chemoradiation. RESULTS: One-hundred and fifty-two consecutive patients with non-metastatic adenocarcinoma or squamous cell esophageal carcinoma treated with chemoradiation were included in the present analysis. The median survival of the whole group was 12 months. The estimated 3- and 5-year survival rates were 24% and 19%, respectively. On multivariate analysis, female sex, weight loss and serum albumin were independent negative predictors of survival. Among 140 patients who survived more than 3 months, weight loss, female sex and therapy with paclitaxel were negatively associated with prognosis, and among 109 patients surviving more than 6 months the dose of cisplatin and surgery were independent prognostic factors. Pathologic complete response was not predictive of prognosis. CONCLUSIONS: Long-term survival is obtained in only about 20% of patients with carcinoma of the esophagus treated with chemoradiation. Female sex, weight loss and low serum albumin are independent indicators of poor prognosis. Among treatment-related factors, higher dose of cisplatin and esophagectomy were independent predictors of better prognosis, while administration of paclitaxel was associated with poor prognosis.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a nádory jícnu $x mortalita $x terapie $7 D004938
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Neoral, Čestmír, $d 1952- $7 xx0000421 $u 1st Clinic of Surgery, Medical Faculty, Palacký University Olomouc, Czech Republic
700    1_
$a Aujeský, René $7 xx0073000 $u First Department of Surgery, Faculty of Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
700    1_
$a Šrámek, Vlastislav $7 xx0246106 $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc 775 20, Czech Republic
700    1_
$a Schneiderka, Petr, $d 1941- $7 jk01111063 $u Department of Clinical Biochemistry, Charles University, Praha, Czech Republic
700    1_
$a Študentová, Hana, $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc 775 20, Czech Republic $d 1979- $7 xx0122256
700    1_
$a Melichar, Bohuslav, $d 1965- $7 skuk0000853 $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc 775 20, Czech Republic; Institute of Molecular and Translational Medicine, Palacký University Medical School and Teaching Hospital, Olomouc 775 20, Czech Republic
700    1_
$a Kohoutek, Milan $7 xx0139956 $u Onkologické centrum, Bat'ova nemocnice, Zlín
700    1_
$a Strážnická, Jana $7 xx0143311 $u Onkologická klinika LF Univerzity Palackého, Olomouc
700    1_
$a Vrba, Radek $7 xx0062746 $u Department of Surgery I, University Hospital Olomouc, Czech Republic
700    1_
$a Juráňová, Jarmila $7 xx0112984 $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine and Dentistry, Palacký University, Olomouc - Czech Republic; Institute of Molecular and Translation Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc - Czech Republic
700    1_
$a Flodr, Patrik, $d 1975- $7 nlk20030127444 $u Department of Pathology, Palacký University Medical School and Teaching Hospital, 77520 Olomouc, Czech Republic
700    1_
$a Macháček, Jindřich, $d 1935- $7 nlk19990073519 $u Clinic of Radiotherapy and Oncology, Medical Faculty, Palacky University, Olomouc, Czechoslovakia
700    1_
$a Cwiertha, Karel $u Department of Oncology, Palacký University Medical School and Teaching Hospital, 77520 Olomouc, Czech Republic
773    0_
$w MED00002025 $t Hepato-gastroenterology $x 0172-6390 $g Roč. 57, č. 102-103 (2010), s. 1145-1149
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21410047 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120816 $b ABA008
991    __
$a 20170427081244 $b ABA008
999    __
$a ok $b bmc $g 949047 $s 784351
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 57 $c 102-103 $d 1145-1149 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology $x MED00002025
LZP    __
$b NLK122 $a Pubmed-20120816/11/02

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace